GlycoMimetics (NASDAQ:GLYC), Five Prime Therapeutics (NASDAQ:FPRX), and Neurocrine Biosciences (NASDAQ:NBIX) may not be household names, but they could be smart additions to biotech portfolios now. Read on to find out how upcoming news could spark interest in GlycoMimetics as soon as next week, a gastric cancer drug could move the needle at Five Prime Therapeutics, and two approved drugs could pave the way to profit at Neurocrine Biosciences.
A high-risk clinical-stage company with news approaching
Todd Campbell (GlycoMimetics): GlycoMimetics has a phase 3 trial underway for uproleselan (formerly GM-1271) in patients with acute myeloid leukemia, and next week, the company will provide additional insight into its phase 2 results at the high-profile American Society of Hematology conference (ASH).
Last year, data for uproleselan in relapsed/refractory AML at ASH sent shares significantly higher on hope for a speedy registrational trial and FDA consideration. Those hopes were dashed earlier this year, though, when management decided a surrogate endpoint that could allow an accelerated OK wasn’t the best long-term strategy. Instead, it’s focusing on overall survival — the gold standard — as its primary endpoint, a decision that… Continue Reading at Fool.com